Skip to content
mapperlab
← Dashboard
Stock

AVNS

AVANOS MEDICAL, INC.
Health CareHealth Care SuppliesLatest close $255 of 27 marquee funds currently hold1 CUSIP mapped
Current holders
5
27 funds tracked
Ever held
8
Current + past
New this quarter
0
Exited this quarter
0

Marquee-fund ownership over time

Feb 16, 2021Nov 14, 2022Aug 14, 2024Feb 17, 2026
Now
5

Current holders

Sorted by tenure (longest first)
FundEntry priceLatest closeReturn on entry
Citadel Advisors$23$25+10%
Two Sigma Investments re-entered$23$25+10%
D.E. Shaw$23$25+10%
AQR Capital Management$23$25+10%
Millennium Management$23$25+10%

“Return on entry” is the price-only move from the fund's first disclosure to today — it ignores any adds, trims, or dividends. A fund that built its position over multiple quarters has a true cost basis somewhere between entry price and latest close; this figure is the upper bound.

Past holders

Funds that exited at some point
FundEntry → ExitReturn
Renaissance Technologies→ $15+21%
Bridgewater Associates→ $17-51%
Maverick Capital 5× in & out→ $23+20%

Insider activity

Form 4 — officers, directors, 10%+ owners

Filed within two business days of each transaction by anyone with material insider status at AVANOS MEDICAL, INC.. Pair with the holders table above as a sanity check: heavy insider buying alongside marquee-fund accumulation is the strongest accumulation signal; heavy insider selling alongside fund exits is the strongest distribution signal.

Filings · last 30d
8
Filings · last 90d
22
Total on file
326
Recent SEC buffer
Most recent
May 12, 2026

30d / 90d windows measured from May 12, 2026 — the most recent Form 4 on file — not from today.

Showing 15 of 326 recent Form 4 filings. Browse all on EDGAR ↗

Fundamentals

XBRL · AVANOS MEDICAL, INC.

Annual figures sourced directly from AVANOS MEDICAL, INC.'s 10-K / 10-Q filings via SEC EDGAR XBRL. Latest fiscal year and the year-over-year change, with up to ten years of history.

Revenue
$701.2M
FY2025+2% YoY
Net income
-$72.9M
FY2025+81% YoY
EPS (diluted)
$-1.57
FY2025+82% YoY
Free cash flow(?)
$74.7M
FY2025-26% YoY

Recent SEC filings

10-K · 10-Q · 8-K · 13D/G · proxy

The most recent material filings for AVANOS MEDICAL, INC. — earnings, material events, ownership disclosures, proxy statements. Form 4 insider activity is shown in the panel above.

Trade history

Every open→close lifecycle across tracked funds
FundOpen dateClose dateOpen priceClose price / currentReturn
Two Sigma InvestmentsQ1 2026open$15$25+66%
Renaissance TechnologiesQ2 2025Q1 2026$12$15+21%
Citadel AdvisorsQ3 2024open$23$25+10%
Two Sigma InvestmentsQ3 2024Q2 2025$23$13-43%
D.E. ShawQ3 2024open$23$25+10%
AQR Capital ManagementQ3 2024open$23$25+10%
Millennium ManagementQ3 2024open$23$25+10%
Maverick CapitalQ1 2024Q3 2024$19$23+20%
Maverick CapitalQ2 2023Q4 2023$23$22-6%
Maverick CapitalQ4 2022Q1 2023$26$30+16%
Maverick CapitalQ3 2021Q1 2022$34$30-10%
Bridgewater AssociatesQ3 2021Q1 2025$34$17-51%
Maverick CapitalQ1 2021Q2 2021$52$40-23%
Caveats
  • Covers only the 27 marquee funds tracked here, not the full institutional universe. A “0 holders” reading does not mean unowned.
  • Heavy funds (Renaissance Technologies, Citadel Advisors, Soros Fund Management, Two Sigma Investments, D.E. Shaw, AQR Capital Management, Millennium Management, Point72 Asset Management) use 8-quarter snapshots, so their pre-2024 history is missing.
  • “Current” reflects each fund's most recent 13F — filings lag the actual trade by up to 45 days; positions shown may have changed since.
  • Cost = price at the entry filing date. Re-entered positions show the most recent open lot.
  • Options, ADRs, and unmapped CUSIPs are excluded from the follower-backtest pipeline that produces these snapshots, so certain holding types won't appear here.